Intuitive Surgical, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Intuitive Surgical, Inc. stock analysis ISRG overview
Slightly Bullish +25

Divergent Trades: Intuitive Surgical's Record Quarter Fails to Unite Investors - AD HOC NEWS

📉 Shares dropped 25% since the start of the year despite a record Q1 where revenue rose 23% to $2.77 billion and EPS beat consensus at $2.50 vs $2.08.

🏦 Institutional investors are diverging sharply; Focus Partners Wealth increased holdings by 42% while PZU SA slashed its stake by 83% and Nicholas Investment Partners sold over 87%.

⚠️ The FDA issued a warning prompting Intuitive Surgical to recall specific models of surgical staplers, creating immediate regulatory risk.

🤖 Competition is intensifying as Chinese manufacturers gain ground in the surgical robot market and OpenAI enters the robotics space.

🇯🇵 A key catalyst is Japan's June 2026 expansion of reimbursement for seven new robotic-assisted procedures, expected to boost volumes in a previously laggard market.

📊 Analyst sentiment remains mixed with 22 out of 31 brokers rating the stock a buy and a mean price target of $571, though Deutsche Bank is a seller at $366.

📉 Technical indicators show weakness with shares trading 15% below the 200-day moving average and an RSI of 44 providing no clear directional signal.

👥 Insider sentiment turned cautious recently as over 7,000 shares were sold by insiders over the past 90 days.

📅 The company is scheduled to report second-quarter results in July with analysts forecasting revenue of $2.82 billion.

Bullish Signals
  • Intuitive Surgical delivered a standout first quarter with revenue growing 23% year-over-year to reach $2.77 billion.
  • Earnings per share of $2.50 significantly exceeded the analyst consensus estimate of $2.08, demonstrating strong profitability.
  • The company installed 431 new da Vinci systems in the quarter, indicating continued demand for its core product.
  • Recurring revenue now accounts for the bulk of the business, providing a stable and predictable cash flow foundation.
  • Major institutional investors like Focus Partners Wealth increased their stakes by nearly 42%, signaling confidence in long-term value.
  • Vanguard enlarged its holding by 11.5% and Sands Capital Management added 2.7% to its position, showing continued accumulation by large funds.
  • Analysts remain broadly bullish with 22 out of 31 brokers rating the stock a buy and a mean price target of $571.
  • Japan's upcoming June 2026 reimbursement expansion for seven new procedures offers a clear path to restoring growth momentum in that region.
Risk Factors
  • Shares have declined roughly 25% since the start of the year, trading significantly below their January peak of EUR 516.50.
  • The FDA issued a warning requiring the recall of specific surgical stapler models, posing an immediate regulatory and reputational risk.
  • Competition is escalating as Chinese manufacturers rapidly gain ground in the surgical robotics market.
  • OpenAI's recent move into robotics has stoked fears of a new, powerful rival entering the medical field.
  • Insider sentiment has turned cautious with more than 7,000 shares sold by insiders over the past 90 days.
  • The stock exhibits high volatility at 36%, keeping traders on edge and increasing short-term price instability.
  • Deutsche Bank stands alone as a seller with a price target of $366, reflecting significant bearish divergence from other analysts.
  • The Relative Strength Index sits at a neutral 44, providing no clear technical support for an immediate upward trend.
Full Analysis
Intuitive Surgical (ISRG) reported a record first quarter with revenue climbing 23% to $2.77 billion and earnings per share of $2.50, significantly beating the analyst consensus of $2.08. Despite these strong fundamentals, shares dropped approximately 25% since the start of the year, trading around EUR 358-360, which is more than 15% below their 200-day moving average and well under the January peak of EUR 516.50. Institutional investor sentiment remains sharply divided following the earnings release. While Sands Capital Management increased its stake by 2.7% to 1.38 million shares, Focus Partners Wealth boosted holdings by nearly 42%, and Vanguard added 11.5%, other major players exited aggressively. Towarzystwo Funduszy Inwestycyjnych PZU SA slashed its position by 83%, Nicholas Investment Partners sold over 87% of their stake, and Deutsche Bank stands alone among analysts as a seller with a price target of $366. The stock faces headwinds from an FDA warning requiring recalls of specific surgical stapler models, growing competition from Chinese robotic manufacturers, and concerns regarding OpenAI's entry into the robotics sector. Insider sentiment has also turned cautious, with over 7,000 shares sold by insiders in the past 90 days. However, a potential catalyst exists in Japan, where the government is set to expand reimbursement for seven new robotic-assisted procedures in June 2026, expected to boost procedure volumes. Technical indicators offer little immediate comfort with the stock maintaining 36% volatility and a neutral Relative Strength Index of 44. Analysts remain broadly positive, with 22 out of 31 brokers rating the stock a buy and a mean price target of approximately $571, though Goldman Sachs recently trimmed its target to $558. The company is due to report second-quarter results in July, with analysts forecasting revenue of $2.82 billion; any miss could accelerate the current decline.